Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Silent Cardiac Impairment in SLE

Arthritis & Rheumatology  |  November 27, 2018

Objective: Cardiac magnetic resonance imaging (MRI) has enabled the assessment of myocardial features, including tissue characteristics and functional changes, in patients with systemic lupus erythematosus (SLE). Echocardiography detects cardiac decompensation. This study was undertaken to investigate the use of cardiac MRI to explore early warning signs of silent cardiac involvement in SLE and determine treatment timing.

Methods: Clinical assessment and cardiac MRI studies were performed in 50 drug-naive patients with new-onset SLE, 60 patients with longstanding SLE and 50 healthy subjects in a three-center, prospective study.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Results: Analysis of cardiac enzymes, the presence and size of regional myocardial fibrosis, as indicated by late gadolinium enhancement, strain changes and biventricular ejection fraction did not indicate cardiac impairment in the patients with new-onset SLE. Native myocardial T1 and extracellular volume (ECV), which are extracellular matrix indices, were elevated in the patients with new-onset SLE (1,369±79 msec vs. 1,092±57 msec in the control group for native T1; 32±5% vs. 24±3% in the control group for ECV; P<0.001 for both). The elevation was independent of SLE disease activity.

Discussion & Conclusion: This study found that 1) drug-naive patients with new-onset SLE, even those with inactive disease, were likely to have silent cardiac impairment; 2) SLE patients could have impairment affecting the matrix, structure or function of the myocardium, and myocardial impairment was related to SLE disease stage; 3) native myocardial T1 values and ECV, rather than currently used clinical rheumatic and cardiac indices, could serve as early detection markers of myocardial injury before late gadolinium enhancement and functional decompensation; and 4) the right ventricle is involved in cardiac impairment prior to the left ventricle in patients without coronary artery disease. Findings for all of the cardiac indices were unrelated to SLE disease activity.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The structural and functional changes in the myocardium were related to SLE disease stage; this association demonstrated the value of early detection of myocardial involvement. Early detection of myocardial injury before the presence of LGE and functional decompensation using native myocardial T1 values and ECV might enable the selection of optimal medical treatments. Further studies with larger sample sizes would be useful for evaluating the effect of this early detection.

Excerpted and adapted from:
Guo Q, Wu L-M, Wang Z, et al. Early detection of silent myocardial impairment in drug-naive patients with new-onset systemic lupus erythematosus. Arthritis Rheumatol. 2018 Dec;70(12):2014–2024.

Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:CardiacMagnetic resonance imaging (MRI)systemic lupus erythematosus (SLE)

Related Articles

    The Heart-SCC Puzzle

    May 1, 2009

    Identifying and treating cardiac involvement in systemic sclerosis can be a challenge

    Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis

    February 18, 2021

    Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.

    Case Report: Is It Cardiac Sarcoidosis or COVID-19 Myocarditis?

    March 12, 2023

    COVID-19 causes myriad cardiac dysfunctions, ranging from mild to fulminant disease, including myocarditis, acute congestive heart failure, cardiogenic shock and sudden cardiac death.1,2 COVID-19 myocarditis can mimic cardiac sarcoidosis clinically and on cardiac imaging, which can lead to diagnostic challenges and treatment delays. We present a case of cardiac sarcoidosis with interval development of metabolic…

    Envision Arthritis Pathology

    April 1, 2008

    MRI advances in RA and OA

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences